^125I粒子植入治疗非小细胞肺癌近期疗效评估  

Implantation of ^(125)I seeds for the treatment of non-small cell lung cancer: evaluation of short-term effect

作　　者：李任飞[1] 王月东[1] 闫龑[1] 杨坡[1] 沙菲[1] 李威[1] 任海涛[1] 

机构地区：[1]哈尔滨医科大学附属第四医院介入血管科,哈尔滨150001

出　　处：《介入放射学杂志》2014年第1期65-68,共4页Journal of Interventional Radiology

基　　金：黑龙江省教育厅2010年度科学技术研究(面上)项目计划(11551290)

摘　　要：目的探讨125I粒子植入治疗非小细胞肺癌(NSCLC)介入综合治疗的近期疗效、可行性、安全性。方法 2010年6月—2012年12月,治疗符合标准肺癌患者为56例,将其分成治疗组A组(24例)和对照组B组(32例)。A组给以支气管动脉化疗药物灌注术,术后给以125I粒子植入术。B组单纯给以支气管动脉化疗药物灌注术。结果 A组中位生存期(22.8±1.9)个月,B组中位生存期(14.2±1.3)个月。A组显著长于B组(P=0.006)。结论125I粒子植入联合动脉化疗治疗中晚期NSCLC与单纯动脉化疗相比能够明显的提高患者的生存质量和延长患者的生存期,是治疗中晚期NSCLC的一种有效的方法,值得临床广泛应用。Objective To assess the short-term effect, feasibility and safety of 125I seeds implantation in treating non-small cell lung cancer. Methods During the period from June 2010 to December 2012 a total of 353 patients with lung cancer were admitted to authors＇ hospital, of whom 56 met the study standards. The 56 cases were divided into study group （n =24） and control group （n = 32）. Bronchial artery chemotherapy with subsequent 125I seeds implantation was carried out in the patients of study group, while only bronchial artery chemotherapy was performed in the patients of control group. The median survival time was compared between the two groups. Results The median survival time of the study group and the control group was （22.8 ± 1.9） months and （14.2 ± 1.3） months respectively. The median survival time of the study group was significantly higher than that of the control group （P = 0.006）. Conclusion Compared with simple bronchial artery chemotherapy, permanent implantation of 125I seeds combined with bronchial artery chemotherapy can significantly improve the quality of life and prolong the survival time as well. Therefore, this technique is an effective therapy for advanced lung cancer and should be recommended in clinical practice.

关 键 词：非小细胞肺癌 支气管动脉化疗药物灌注 125I粒子植入 计算机治疗计划系统 

分 类 号：R734.2[医药卫生—肿瘤]